Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer

Pharmacogenomics

Volumn 9, Issue 6, 2008, Pages 681-690

  Vallböhmer, Daniel ^a   Kuhn, Elmar ^a   Warnecke Eberz, Ute ^a   Brabender, Jan ^a   Hoffmann, Andreas C ^a   Metzger, Ralf ^a   Baldus, Stephan E ^b   Drebber, Uta ^a   Hoelscher, Arnulf H ^a   Schneider, Paul M ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Esophageal cancer; Neoadjuvant therapy; Response medication; Survivin

Indexed keywords

CISPLATIN; FLUOROURACIL; SURVIVIN; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR PROTEIN;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; SURGICAL TECHNIQUE; TREATMENT RESPONSE; TUMOR BIOPSY; ADULT; AGED; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ESOPHAGUS TUMOR; FEMALE; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; TREATMENT FAILURE;

EID: 48949119287     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.6.681     Document Type: Article

References (35)

1. Jemal A, Siegel R. Ward E et al.: Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Wei JT, Shaheen N: The changing epidemiology of esophageal adenocarcinoma. Semin. Gastrointest. Dis. 14, 112-127 (2003).
3. Pohl H, Welch HG: The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl Cancer Inst. 97, 142-146 (2005).
4. Ando N, Ozawa S, Kitagawa Y. Shinozawa Y, Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann. Surg. 232, 225-232 (2000).
5. Whooley BF, Law S, Murthy SC, Alexandrou A, Wong J: Analysis of reduced death and complication rates after esophageal resection. Ann. Surg. 233, 338-344 (2001).
6. Refaely Y, Krasna, MJ: Multimodality therapy for esophageal cancer. Surg. Clin. North Am. 82, 729-746 (2002).
7. Thomas CR Jr: Current and ongoing progress in the therapy for resectable esophageal cancer. Dis. Esophagus 18, 211-214 (2005).
8. Rouvelas I, Zeng W, Lindblad M, Viklund P. Ye W, Lagergren J: Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. World J. Surg. 30, 2182-2190 (2006).
9. Urba SC, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 19. 305-313 (2001).
10. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335, 462-467 (1996).
11. Greer SE. Goodney PP. Sutton JE et al.: Neoadjuvant chemoradiotherapy for esophageal carcinoma: a meta-analysis. Surgery 137, 172-177 (2005).
12. Kelsen DP: Multimodality therapy of esophageal cancer: an update. Cancer J. 6(Suppl. 2), S177-S181 (2000).
13. Brucher BL, Stein HJ, Zimmermann F et al.: Responders benefit from neoadjuvant chemoradiation in esophageal squamous cell carcinoma: results of a prospective Phase-II trial. Eur. J. Surg. Oncol. 30, 963-971 (2004).
14. Ambrosini U. Adida U, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917-921 (1997).
15. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP: Structure of the human anti-apoptotic protein survivin reveals a climeric arrangement. Nat. Struct. Biol. 7, 602-608 (2000).
16. Fortugno P. Wall NR. Giodini A et al.: Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell Sci. 115, 575-585 (2002).
17. Pennati M, Folini M, Zaffaroni N: Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 28, 1133-1139 (2007).
18. Nemoto T, Kitagawa M, Hasegawa M et al.: Expression of IAP family proteins in esophageal cancer. Exp. Mol. Pathol. 76, 253-259 (2004).
19. Grabowski P, Kuhnel T. Muhr-Wilkenshoff F et al.: Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br. J. Cancer 88, 115-119 (2003).
20. Kato J, Kuwabara Y, Mitani M et al.: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95, 92-95 (2001).
21. Vallbohmer D, Peters JH, Oh D et al.: Survivin, a potential biomarker in the development of Barrett's adenocarcinoma. Surgery 138, 701-706 (2005).
22. Warnecke-Eberz U, Hokita S, Xi H et al.: Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant chemoradiation in esophageal cancer. Oncol. Rep. 13, 1241-1246 (2005).
23. Baldus SE, Mönig SP, Schröder W et al.: Regression of oesophageal carcinomas after neoadjuvant chemoradiation: criteria of the histopathological evaluation. Pathologe 25, 421-427 (2004).
24. Schneider PM, Baldus SE, Metzger R et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant chemoradiation for esophageal cancer: Implications for response classification. Ann. Surg. 242, 684-692 (2005).
25. Sobin LH, Wittekind CH: International Union Against Cancer (UIC C) TNM Classification of Malignant Tumors, 5th Edition. John Wiley and Sons, NY, USA (1997)
26. Xi H, Baldus SE, Warnecke-Eberz U et al.: High cyclooxygenase-2 expression following neoadjuvant chemoradiation is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clin. Cancer Res. 11, 8341 8347 (2005).
27. Li F, Ambrosini G, Chu EY et al.: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 496, 580-584 (1998).
28. Dutta T, Sharma H, Kumar L, et al.: Neoadjuvant chemotherapy for epithelial ovarian cancer - role of apoptosis. Cancer Chemother. Pharmacol. 56, 427-435 (2005).
29. Mega S, Miyamoto M, Li L et al.: Immunohistochemical analysis of nuclear survivin expression in esophageal squamous cell carcinoma. Dis. Esophagus 19, 355-359 (2006).
30. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ. Clark GW: Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy. J Gastrointest. Surg. 7, 77-87 (2003).
31. Asanuma K, Moriai R, Yajima T et al.: Survivin as a radioresistance factor in pancreatic cancer. Jpn J. Cancer Res. 91, 1204-1209 (2000).
32. Chakravarti A, Zhai GG, Zhang M et al.: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23, 7494 -7506 (2004).
33. Wang Y, Zhu H, Quan L et al.: Downregulation of survivin by RNAi inhibits the growth of esophageal carcinoma cells. Cancer Biol. Ther. 4, 974-978 (2005).
34. Karavasilis V, Mita A, Hudes G et al.: Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). J. Clin. Oncol. ASCO Annual Meeting Frocedinp Part I. Vol 25, No. 18S, 5135 (2007).
35. Stauber RH, Mann W, Knauer SK: Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res. 67, 5999-6002 (2007).